Xiaofeng Wu Selected Research

Xiaofeng Wu Research Topics

Disease

35	Neoplasms (Cancer) 04/2022 - 06/2002
15	Infections 01/2021 - 03/2003
6	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 06/2002
5	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2002
5	Virus Diseases (Viral Diseases) 01/2021 - 01/2020
4	Hypoxia (Hypoxemia) 01/2022 - 03/2015
4	Inflammation (Inflammations) 01/2021 - 04/2007
3	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2018
3	Carcinogenesis 10/2021 - 04/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2021 - 01/2019
3	Colonic Neoplasms (Colon Cancer) 01/2021 - 03/2009
3	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 01/2017
3	Stroke (Strokes) 10/2018 - 03/2010
2	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 03/2010
2	Obstructive Sleep Apnea 01/2022 - 01/2022
2	Fibrosis (Cirrhosis) 11/2020 - 01/2020
2	Osteoarthritis 08/2020 - 01/2018
2	Wounds and Injuries (Trauma) 10/2018 - 09/2015
2	Brain Ischemia (Cerebral Ischemia) 03/2015 - 01/2013
2	Starvation 10/2005 - 10/2005
1	Adenocarcinoma 10/2022
1	Autoimmune Diseases (Autoimmune Disease) 04/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Apnea 01/2022
1	Cholangiocarcinoma 01/2022
1	Klatskin Tumor 01/2022
1	Exanthema (Rash) 01/2022
1	Coronary Disease (Coronary Heart Disease) 01/2022
1	Neutropenia 01/2022
1	Sleep Deprivation 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Body Weight (Weight, Body) 01/2022
1	Tics (Tic) 01/2022
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 12/2021
1	Hypersensitivity (Allergy) 12/2021
1	COVID-19 05/2021
1	Arthritis (Polyarthritis) 03/2021

Drug/Important Bio-Agent (IBA)

25	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2004
8	Pharmaceutical PreparationsIBA 01/2022 - 03/2010
8	Messenger RNA (mRNA)IBA 01/2022 - 06/2002
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2016
6	EnzymesIBA 10/2021 - 11/2006
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 05/2004
4	Interleukin-6 (Interleukin 6)IBA 01/2020 - 01/2013
4	CytokinesIBA 10/2019 - 01/2013
3	ChromatinIBA 01/2022 - 01/2019
3	NitrogenIBA 01/2022 - 10/2005
3	Fluorescent Dyes (Fluorescent Probes)IBA 01/2021 - 01/2016
2	ChemokinesIBA 04/2022 - 01/2021
2	Immune Checkpoint InhibitorsIBA 01/2022 - 11/2020
2	6-methyladenineIBA 01/2022 - 10/2021
2	N-methyladenosineIBA 01/2022 - 10/2021
2	camrelizumabIBA 01/2022 - 11/2020
2	MicroRNAs (MicroRNA)IBA 10/2021 - 01/2021
2	Caspase 3 (Caspase-3)IBA 08/2021 - 08/2020
2	cytochalasin HIBA 01/2021 - 01/2019
2	Phosphotransferases (Kinase)IBA 01/2021 - 01/2011
2	InterferonsIBA 11/2020 - 10/2020
2	SofosbuvirIBA 11/2020 - 01/2020
2	Therapeutic UsesIBA 10/2019 - 11/2016
2	Toll-Like Receptors (Toll-Like Receptor)IBA 10/2018 - 05/2014
2	Docetaxel (Taxotere)FDA Link 01/2017 - 01/2017
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 11/2016 - 09/2015
2	Peptide Hydrolases (Proteases)FDA Link 01/2016 - 01/2007
2	Viral DNAIBA 10/2015 - 03/2003
2	Protein Isoforms (Isoforms)IBA 01/2015 - 06/2014
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2015 - 04/2014
2	Biological ProductsIBA 06/2014 - 04/2014
2	Histone Deacetylase InhibitorsIBA 07/2011 - 03/2010
2	Amino Acids FDA Link 06/2011 - 05/2004
2	LigandsIBA 04/2007 - 05/2004
2	DNA (Deoxyribonucleic Acid)IBA 10/2005 - 05/2004
1	Chemokine CXCL10IBA 04/2022
1	sintilimabIBA 01/2022
1	Oxygen (Dioxygen)IBA 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	NLR ProteinsIBA 01/2022
1	AlbuminsIBA 01/2022
1	6-propylchromone-2-carboxylic acid (PCCA)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	anlotinibIBA 01/2022
1	Sirolimus (Rapamycin)FDA Link 01/2022
1	apatinibIBA 01/2022
1	CreatinineIBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	Urea (Carbamide)FDA LinkGeneric 01/2022
1	TOR Serine-Threonine KinasesIBA 01/2022
1	Interleukin-1 Receptor-Associated KinasesIBA 12/2021
1	Butyric Acid (Butanoic Acid)IBA 12/2021
1	SiliconIBA 10/2021
1	Exonucleases (3' 5' Exonuclease)IBA 10/2021
1	Death-Associated Protein KinasesIBA 10/2021

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 05/2021 - 06/2018
3	Acupuncture Points (Acupuncture Point) 09/2020 - 03/2015
1	Adjuvant Chemotherapy 10/2022
1	Neoadjuvant Therapy 01/2022
1	Perioperative Period 01/2022
1	Immunotherapy 01/2022
1	Aftercare (After-Treatment) 01/2022
1	Precision Medicine 08/2021